1 July 2020 - EMA has endorsed a joint statement on prioritisation of COVID-19 clinical trials published by the International Coalition of Medicines Regulatory Authorities. 

Medicines regulators from around the world have jointly developed this statement to step up global collaboration to facilitate and expedite the development and evaluation of therapeutics, diagnostics and vaccines against COVID-19.

“As the COVID-19 pandemic continues to evolve in many countries, we have seen unprecedented global collaboration and a surge in research and development of potential medicines and vaccines against coronavirus disease around the world,” said Guido Rasi, Chair of ICMRA and EMA’s Executive Director. “We, as regulators, support the trials that are providing robust and reliable results required for regulatory decision-making, and evidence that can be used across the globe for all patients affected by COVID-19.”

Read EMA press release